Genome wide expression analysis of the impact of rapamycin and DOT1L inhibitor treatment upon the progression of replicative senescence

BJ fibroblasts were grown in the continued presence of either rapamycin, the DOT1L inhibitor EPZ-5676, rapamycin + EPZ-5676, or control treatment, and collected for RNA-seq at young-quiescent, intermediate-quiescent, or senescent cell states. BJ fibroblasts were grown in the continued presence of either rapamycin (10nM), the DOT1L inhibitor EPZ-5676 (500nM), rapamycin (10nM) + EPZ-5676 (500nM), or control treatment, and collected for RNA-seq at young-quiescent, intermediate-quiescent, or senescent cell states. RNA-seq tag density across gene bodies was determined for each sample and compared between different cell stages of senescence as well as between treatment and control samples.